Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Everlight Chemical Industrial Corporation (1711.TW)
Taipei, TW
Everlight Chemical Industrial Corporation, founded in Taipei, Taiwan, in 1972, operates as a global producer and distributor of a diverse array of chemical products. Its extensive market reach spans Taiwan, the broader Asian region, the United States, Europe, and other international territories. The company's product portfolio encompasses a comprehensive range of dyes, including those for textiles, leather, inkjet printing, metals, paper, and advanced functional chemicals for fabric applications, digital textile solutions, and solar-sensitized dyes. Furthermore, Everlight provides specialized chemical additives such as light stabilizers, crucial for enhancing the durability of weather-resistant coatings and plastics, alongside anti-yellowing agents for polyurethane and thermoplastic polyurethane materials, and essential raw materials for sunscreen cosmetic formulations. In the pharmaceutical sector, it develops and manufactures active pharmaceutical ingredients (APIs), notably prostaglandin APIs, as well as APIs for treating cardiovascular conditions and Parkinson's disease. For the electronics industry, the corporation supplies high-performance materials like photoresists, developers, polishing solutions, and sophisticated functional surface nano-coatings designed for integrated circuits (ICs), liquid crystal displays (LCDs), light-emitting diodes (LEDs), and touch panel (TP) applications. Additionally, it produces and markets imaging consumables, including toner and cartridges, compatible with laser printers, photocopiers, and fax machines. Beyond manufacturing, the company actively engages in the trading of chemical products and raw materials, offers expert technical consulting services, and produces pigments, toners, and specialized chemicals for electronic applications.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.39% | -12.07% | +16.84% | +101.58% | +165.63% | +166.32% | +197.38% | +154.36% | +177.93% | +176.72% | +530.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%-7.3% Q1'26: +5.4% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-147.7% Q1'26: +33.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+1.1% Q1'26: +1.2% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%-2.6% Q1'26: +1.8% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%-1.9% Q1'26: +1.1% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+1.7% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×6.61× Q1'26: 3.94× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.54B
est: 9.54B (0.0%)
|
9.45B
est: 9.45B (+0.0%)
|
9.17B
est: 9.17B (0.0%)
|
9.62B
est: 9.63B (-0.1%)
|
9.33B
est: 9.45B (-1.2%)
|
7.77B
est: 9.17B (-15.3%)
|
9.20B
est: 9.63B (-4.4%)
|
8.89B
est: 9.84B (-9.7%)
|
7.86B
est: 9.04B (-13.1%)
|
8.17B
est: 9.45B (-13.6%)
|
7.57B
est: 9.45B (-19.9%)
|
9.17B
9.17B – 9.17B
-3.0% YoY
|
9.63B
9.63B – 9.63B
+5.0% YoY
|
9.84B
9.84B – 9.84B
+2.2% YoY
|
9.04B
9.04B – 9.04B
-8.1% YoY
|
| EBITDA |
1.17B
est: 1.25B (-6.4%)
|
1.04B
est: 1.24B (-15.8%)
|
966.39M
est: 1.20B (-19.8%)
|
1.15B
est: 1.26B (-9.3%)
|
1.25B
est: 1.24B (+0.8%)
|
1.06B
est: 1.20B (-12.1%)
|
1.36B
est: 1.26B (+7.5%)
|
1.22B
est: 1.29B (-5.4%)
|
853.90M
est: 1.19B (-28.1%)
|
1.03B
est: 1.10B (-5.8%)
|
452.77M
est: 1.10B (-58.7%)
|
1.06B
1.06B – 1.06B
-3.0% YoY
|
1.12B
1.12B – 1.12B
+5.0% YoY
|
1.14B
1.14B – 1.14B
+2.2% YoY
|
1.05B
1.05B – 1.05B
-8.1% YoY
|
| EBIT |
672.55M
est: 476.55M (+41.1%)
|
467.44M
est: 472.05M (-1.0%)
|
544.08M
est: 458.04M (+18.8%)
|
610.37M
est: 480.89M (+26.9%)
|
552.35M
est: 472.05M (+17.0%)
|
328.70M
est: 458.04M (-28.2%)
|
646.02M
est: 480.89M (+34.3%)
|
554.92M
est: 491.61M (+12.9%)
|
202.16M
est: 451.67M (-55.2%)
|
370.88M
est: 337.77M (+9.8%)
|
-196.00M
est: 337.77M (-158.0%)
|
327.75M
327.75M – 327.75M
-3.0% YoY
|
344.10M
344.10M – 344.10M
+5.0% YoY
|
351.77M
351.77M – 351.77M
+2.2% YoY
|
323.19M
323.19M – 323.19M
-8.1% YoY
|
| Net Income |
565.35M
est: 538.05M (+5.1%)
|
468.53M
est: 477.20M (-1.8%)
|
366.14M
est: 367.50M (-0.4%)
|
401.98M
est: 411.38M (-2.3%)
|
362.45M
est: 477.20M (-24.0%)
|
213.28M
est: 367.50M (-42.0%)
|
472.97M
est: 411.38M (+15.0%)
|
374.43M
est: 504.62M (-25.8%)
|
85.87M
est: 340.07M (-74.8%)
|
243.59M
est: 485.44M (-49.8%)
|
-136.16M
est: 485.44M (-128.0%)
|
373.85M
373.85M – 373.85M
-23.0% YoY
|
418.49M
418.49M – 418.49M
+11.9% YoY
|
513.34M
513.34M – 513.34M
+22.7% YoY
|
345.95M
345.95M – 345.95M
-32.6% YoY
|
| SGA |
1.22B
est: 1.35B (-9.6%)
|
1.22B
est: 1.33B (-8.1%)
|
1.20B
est: 1.29B (-7.1%)
|
1.21B
est: 1.36B (-11.0%)
|
1.19B
est: 1.33B (-10.5%)
|
991.19M
est: 1.29B (-23.4%)
|
1.25B
est: 1.36B (-7.8%)
|
1.25B
est: 1.39B (-9.7%)
|
1.17B
est: 1.28B (-8.4%)
|
1.24B
est: 1.41B (-11.7%)
|
1.26B
est: 1.41B (-10.5%)
|
1.36B
1.36B – 1.36B
-3.0% YoY
|
1.43B
1.43B – 1.43B
+5.0% YoY
|
1.46B
1.46B – 1.46B
+2.2% YoY
|
1.35B
1.35B – 1.35B
-8.1% YoY
|
| EPS |
1.03
est: 0.98 (+5.0%)
|
0.86
est: 0.87 (-1.1%)
|
0.67
est: 0.67 (+0.0%)
|
0.73
est: 0.75 (-2.7%)
|
0.66
est: 0.87 (-24.1%)
|
0.39
est: 0.67 (-41.8%)
|
0.86
est: 0.75 (+14.7%)
|
0.68
est: 0.92 (-26.1%)
|
0.16
est: 0.62 (-74.2%)
|
0.44
est: 0.87 (-49.4%)
|
-0.21
est: 0.87 (-124.1%)
|
0.67
0.67 – 0.67
-23.0% YoY
|
0.75
0.75 – 0.75
+11.9% YoY
|
0.92
0.92 – 0.92
+22.7% YoY
|
0.62
0.62 – 0.62
-32.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.05% | 342.1K | 0.65% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.04% | 53.1K | 0.42% |
| 3 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.04% | 741.3K | 0.58% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.02% | 398.2K | 0.46% |
| 5 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.02% | 101.0K | 0.44% |
| 6 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.23M | 0.06% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.01% | 1.14M | 0.39% |
| 8 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.01% | 24.4K | 0.33% |
| 9 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 35.0K | 0.56% |
| 10 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.01% | 25.9K | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bai-Li Sung | Head of Resource Management Division | — | male |
| Bao-Kun Lai | Head of Technical Marketing Division | — | male |
| Che-Jen Sun | Head of Electronic Chemicals | — | male |
| Chong-Kun Hsiao | Head of Operation Unit 1 of Color Chemicals | — | male |
| Hui-Ching Huang | Head of Product Responsibility Division | — | female |
| Jen-Yang Liang | Head of Specialty Chemicals | — | male |
| Kuo-Pin Weng | Head of Financial Division and Supervisor of Financial & Accounting Department | — | male |
| Si-Feng Chen | Head of Pharmaceutical Chemicals Q&C Division | — | male |
| Wei-Wang Chen | GM & Director | — | — |
| Yao-Xing Huang | Head of Specialty Chemicals Technics Division | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1711.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
